Photocure

This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (June 2019)

Photocure ASA

Company type	Allmennaksjeselskap
Traded as	OSE: PHO
Industry	Pharmaceutical
Founded	1993
Headquarters	Oslo, Norway
Key people	Daniel Schneider (CEO), Jan Egberts (Chairperson of the board)
Products	Hexvix Cysview
Revenue	NOK 150 million [1]
Number of employees	70
Website	www.photocure.com

Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy.^{[citation needed]}